Local Therapy Improves Survival for Early Recurrence After Resection of Colorectal Liver Metastases

摘要

Background. Early recurrence following hepatectomy for colorectal liver metastases (CLM) is associated with worse survival; yet, impact of further local therapy is unclear. We sought to evaluate whether local therapy benefits patients with early recurrence following hepatectomy for CLM. Methods. Clinicopathologic and survival outcomes of patients managed with hepatectomy for CLM (1/2001-12/2020) were queried from a prospectively maintained database. Timing of recurrence was stratified as early (recurrence-free survival RFS 12 months). Local therapy was defined as ablation, resection, or radiation. Results. Of 671 patients, 541 (81) recurred with 189 (28) early, 180 (27) intermediate, and 172 (26) later recurrences. Local therapy for recurrence resulted in improved survival, regardless of recurrence timing (early 78 vs. 32 months, intermediate 72 vs. 39 months, later 132 vs. 65 months, all p<0.001). Following recurrence, treatment with local therapy (hazard ratio HR =0.24), liver and extrahepatic recurrence (HR=1.81), RAS+TP53 co-mutation (HR= 1.52), and SMAD4 mutation (HR= 1.92) were independently associated with overall survival (all p < 0.002). Among patients with recurrence treated by local therapy, patients older than 65 years (HR 1.79), liver and extrahepatic recurrence (HR 2.05), primary site or other recurrence (HR 1.90), RAS-TP53 co-mutation (HR 1.63), and SMAD4 mutation (HR 2.06) had shorter post-local therapy survival (all p< 0.04). Conclusions. While most patients recur after hepatectomy for CLM, local therapy may result in long-term survival despite early recurrence. Somatic mutational profiling may help to guide the multidisciplinary consideration of local therapy after recurrence.